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Abstract: 1 
In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are 2 
responsible for disease persistence despite TKI.  Based on in vitro data, CHOICES (CHlorOquine and 3 
Imatinib Combination to Eliminate Stem cells) was an international, randomised phase II trial designed 4 
to study the safety and efficacy of imatinib (IM) and hydroxychloroquine (HCQ) compared to IM alone in 5 
CP-CML patients in major cytogenetic remission with residual disease detectable by qPCR. Sixty-two 6 
patients were randomly assigned to either arm. Treatment ‘successes’ was the primary end-point, 7 
defined as ≥0.5 log reduction in 12-month qPCR level from trial entry. Selected secondary study end-8 
points were 24-month treatment ‘successes’, molecular response and progression at 12 and 24 months, 9 
comparison of IM levels, and achievement of blood HCQ levels >2000ng/ml.  At 12 months, there was no 10 
difference in ‘success’ rate (p=0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (p=0.21).  At 24 11 
months, the ‘success’ rate was 20.8% higher with IM/HCQ (p=0.059).  No patients progressed. 12 
Seventeen adverse events, including four serious adverse reactions, were reported; diarrhoea occurred 13 
more frequently with combination.  IM/HCQ is tolerable in CP-CML, with modest improvement in qPCR 14 
levels at 12 and 24 months, suggesting autophagy inhibition maybe of clinical value in CP-CML. 15 
 16 
(200 words) 17 
 18 
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 20 
 21 
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 24 
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Chronic myeloid leukaemia (CML) is a clonal myeloproliferative neoplasm that originates from a 25 
constitutively active tyrosine kinase, BCR-ABL, resulting from a reciprocal translocation between 26 
chromosomes 9 and 22 1, 2.  Upregulation of BCR-ABL drives disordered myelopoiesis through aberrant 27 
metabolism and expression of downstream signalling pathways 3, 4.  Despite a targeted therapeutic 28 
approach, disease persistence is driven by a small residual BCR-ABL1 positive (+) stem cell population 5-9.  29 
This can lead to disease progression to the more acute form, termed blast crisis, which carries a very 30 
poor prognosis 10.  Measures to enhance the elimination of residual disease are therefore required to 31 
further improve outcomes and increase the number of patients obtaining deep molecular remission 32 
(DMR; defined as ≥4-log reduction in BCR-ABL transcript levels) who can be considered for 33 
discontinuation of TKI treatment and long-lasting treatment-free remission (TFR) 11-13.  34 
 35 
Autophagy, an evolutionarily conserved catabolic process 14, is induced following in vitro tyrosine kinase 36 
inhibition (TKI) of primitive CML cells 15.  While autophagy has been shown to suppress cancer initiation 37 
in mouse models, an increasing amount of evidence suggests it plays a critical pro-survival role following 38 
therapeutic stress 16.  Furthermore, pharmacological autophagy inhibition, using the non-specific 39 
autophagy inhibitor, chloroquine (CQ), enhances the effect of TKI on functionally defined CML stem cells 40 
compared to Imatinib (IM) or CQ alone 15. 41 
 42 
Based on these findings, we designed the CHOICES (CHlorOquine and Imatinib Combination to Eliminate 43 
Stem cells) trial (NCT01227135); a randomised, open-label, phase II clinical trial comparing the 44 
combination of IM and hydroxychloroquine (HCQ) with standard-of-care IM in chronic phase (CP)-CML 45 
patients in major cytogenetic response (MCyR) with residual disease detectable by qPCR after at least 46 
one year of IM treatment.  This is the first clinical trial of autophagy inhibition in leukaemia and provides 47 
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a proof-of-concept for further development and testing of more potent and/or specific autophagy 48 
inhibitors for use in future leukaemia trials 17. 49 
 50 
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Methods: 72 
Patients: 73 
Eligible patients were 18 years or older with CP-CML.  Patients had been treated with, and tolerated, IM 74 
for more than 12 months, achieved at least MCyR and remained BCR-ABL+ by qPCR.  A stable dose of IM 75 
for 6 months prior to study entry was a prerequisite.  Eligible patients had an Eastern Cooperative 76 
Oncology Group (ECOG) performance status (PS) of 0 to 2 and adequate end-organ and marrow 77 
function, with no uncontrolled significant illness.  Informed consent was obtained in accordance with 78 
the Declaration of Helsinki and with approval from Greater Glasgow and Clyde NHS Trust Ethics 79 
Committee.  The “Hospices Civils de Lyon” (Lyon, France) were the sponsors within France.  Following 80 
enrolment, the Cancer Research UK Clinical Trials Unit, Glasgow, were contacted to verify eligibility and 81 
undertake randomisation.  Exclusion criteria are listed in table I.  82 
Study Design and Objectives: 83 
This was an international multicenter, two-arm parallel, open-label, randomised phase II trial with a 84 
safety run-in, designed to study the safety and efficacy of HCQ in combination with IM (NCT01227135).  85 
Patients were randomly assigned at a one-to-one allocation ratio to IM in combination with HCQ 86 
(IM/HCQ) or IM alone.  Random assignment was stratified using a minimisation algorithm, incorporating 87 
the following factors:   88 
• Baseline PCR level (<3 logs below baseline, ≥3 logs below baseline) 89 
• Time on IM (12-24 months, 24 - <36 months, ≥36 months) 90 
• Daily IM dose (<400mg, 400 - <600mg, 600 - 800mg) 91 
• Site 92 
All patients continued once daily dosing of IM throughout the 24-month study period. Patients on the 93 
IM/HCQ arm received a maximum of 12 four-weekly cycles of combination treatment (48 weeks).    94 
Patients were followed-up for a further 12 cycles, taking each patient’s total study participation to a 95 
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maximum of 96 weeks. Orally administered HCQ was started at 800mg/day as 400mg twice daily.  In the 96 
case of missed doses, patients were advised to take the drug on the same day if within 6 hours, or the 97 
dose was withheld until the next scheduled dose.  For dose reduction, 600mg/day was divided into 98 
400mg every morning and 200mg every night, and 400mg/day into 200mg twice daily.  Recruitment was 99 
temporarily stopped for 6 weeks once 6 patients were randomly allocated to IM/HCQ to monitor for 100 
evidence of any dose limiting toxicity (DLT).  DLT was defined as i) any grade 3 or 4 non-haematological 101 
toxicity that was/possibly was attributed to the study drug, excluding grade 3 nausea, vomiting and 102 
diarrhoea controllable by concomitant therapy, or ii) any grade 3 or 4 haematological toxicity that could 103 
not be corrected by granulocyte colony-stimulating factor. 104 
Definitions of end points: 105 
The primary study end-point was the proportion of treatment ‘successes’, defined as patients who had 106 
≥0.5 log reduction (approximately 3-fold reduction) in their 12-month BCR-ABL1 qPCR levels from trial 107 
entry.  Patients who withdrew before the 12-month assessment or who had an increase in IM dose prior 108 
to the assessment were classified as treatment ‘failures’ in the primary end-point analysis.  To avoid bias 109 
in the primary endpoint, the assessment of qPCR levels was performed blind to the study treatment 110 
allocation.  The secondary study end-points were the proportion of treatment ‘successes’ at 24 months, 111 
molecular response at 12 and 24 months, comparison of IM levels (using metabolite CGP-74588) 112 
between study arms at 12 and 24 months (supplemental methods), and the proportion of patients who 113 
achieved therapeutic whole blood HCQ levels >2000ng/ml at 12 and 24 months (supplemental 114 
methods).  Patients who withdrew prior to 24 months were classified as treatment ‘failures’ in 115 
secondary end-point analyses (figure 1). 116 
BCR-ABL1 detection: 117 
Monitoring for BCR-ABL1:ABL1 was performed centrally at Imperial Molecular Pathology Laboratory, 118 
London, and all BCR-ABL1:ABL1 ratios were expressed according to the international scale (IS).  Baseline 119 
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BCR-ABL1:ABL1 was documented from local laboratory analysis (table 2) and repeated centrally to 120 
enable subsequent longitudinal analysis of response.  MMR was defined as 0.1%(IS) or lower, with 10,000 121 
or more ABL1 control transcripts.  122 
Statistical method: 123 
Using retrospective study data 18, approximately 30% of patients fulfilling the entry criteria were 124 
expected to obtain a ≥0.5 log decrease in BCR-ABL1 qPCR levels after 12 months of IM treatment 125 
(treatment ‘success’).  To detect an increase in the proportion of treatment ‘successes’ from 30% to 50% 126 
required 33 patients per arm (80% power, 20% 1-sided level of statistical significance).  Randomisation 127 
was undertaken centrally using a computerised algorithm, which incorporated a random element to 128 
remove predictability and ensure groups were well-matched, using a minimisation approach (described 129 
above).  At the end of the randomisation process, the patient’s treatment allocation and unique 130 
identifier were generated.  131 
 132 
Analyses were performed using SPSS 22.0.0.0 (SPSS, Chicago, IL) and were conducted on an intention-to-133 
treat (ITT) basis.  The comparisons between the study arms of “successes”/”failures”, progression, and 134 
molecular response rates used Fisher’s exact test.  95% confidence intervals for the difference in 135 
proportions were calculated using method 10 in RG Newcombe 19.  Molecular response rates, IM plasma 136 
levels and the most severe common terminology criteria of adverse events (CTCAE v4.0) grade observed 137 
per patient for individual adverse events over the 12-month study period and the 12-month follow-up 138 
period were compared between the study arms using the Mann-Whitney U test.  Statistical analyses of 139 
in vitro data and continuous BCR-ABL1:ABL1 qPCR data were performed using the ‘NADA’ package in R 140 
(v3.3.3) to allow interpretation of values below the limit of detection 20, 21.  Adjustments for multiple 141 
testing were made, where appropriate, using the false discovery rate (FDR) approach 22, using the 142 
p.adjust function (‘fdr’ option) in R.  143 
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Results: 144 
Patient characteristics: 145 
From 22 April 2010 to 31 December 2014, 62 patients were randomly assigned to IM (n=30) or IM/HCQ 146 
(n=32).  Demographic characteristics were similar between arms (table 2).  Pre-treatment peripheral 147 
blood (PB) qPCR was available for all patients enrolled, with median BCR-ABL1:ABL1 ratio of 0.046% 148 
(interquartile range (IQR) 0.011% to 0.118%) in the IM arm, and 0.034% (IQR 0.012% to 0.047%) in the 149 
IM/HCQ arm.  Duration of IM prior to study entry was similar.  Additional chromosomal abnormalities 150 
within the Philadelphia + clone were identified at CML diagnosis in 2 patients in the IM arm (one with a 151 
variant Philadelphia chromosomal translocation and one with deletion of chromosome 12), and 3 in the 152 
IM/HCQ arm (trisomy 21, deletion of chromosome 9, and a double Philadelphia chromosome 153 
abnormality).  One patient in the IM arm withdrew from the trial prior to trial initiation and received no 154 
treatment on study; 6 patients withdrew consent during the study (figure 1).  Patients were followed-up 155 
for a minimum of 24 months.  156 
Molecular efficacy: 157 
No statistical difference was demonstrated in ‘success’ rate between arms at 12 months (1.2% lower 158 
with IM/HCQ vs IM; 95% CI 21.1% lower to 18.4% higher; 1-sided p=0.58; 2-sided p=0.99) (table 3).  159 
Patients who withdrew before the 12-month assessment (n=11) or who had an increase in IM dose prior 160 
to the assessment (n=1) were classified as ‘failures’ (n=5 with IM; n=7 with IM/HCQ), which may account 161 
for this.  At 12 months, MMR was achieved/maintained in 66.7% on IM versus 71.9% on IM/HCQ (5.2% 162 
higher in the IM/HCQ arm; 95% CI: 17.1% lower to 27.1% higher; 1-sided p=0.43; 2-sided p=0.78). 163 
At 24 months, ‘success’ rate in the IM/HCQ arm was 20.8% higher than the IM arm (95% CI: 1.5% lower 164 
to 40.4% higher; 1-sided p = 0.059; 2-sided p = 0.090).  Patients with a sample approximately 90 days 165 
prior to the expected 24-month time point, or at any time after, were eligible for analysis, with the 166 
closest sample to the scheduled 24-month date (before or after) chosen.  The numbers classed as 167 
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‘failures’ due to failure to achieve the appropriate log reduction in BCR-ABL1:ABL1IS within the 168 
acceptable window of the 24-month expected assessment time was higher with IM (n=19; 76%) 169 
compared to IM/HCQ (n=13; 65.0%).  At 24 months, DMR/MMR was achieved/maintained in 66.7% with 170 
IM, and 75.0% with IM/HCQ (8.3% higher in the IM/HCQ arm; 95% CI: 13.8% lower to 29.7% higher).  171 
There was a slight, but not significant, difference in rates of molecular response between the arms (1-172 
sided p=0.33; 2-sided p=0.58) at the 1-sided 20% significance level.    There was no significant difference 173 
between depth of molecular response at 12 or 24 months.  No confirmed or suspected progressions at 174 
any time during the study were identified. 175 
In view of the variation of BCR-ABL1:ABL1 ratio between patients (table 2) at trial entry, a post hoc 176 
analysis was performed using the median BCR-ABL1:ABL1 ratio (0.0305%) to determine sub-groups of 177 
‘high’ and ‘low’ BCR-ABL1:ABL1 expression at trial entry.  MMR was not used as this led to a significant 178 
imbalance in subgroup sizes between the arms and would not have been informative.  In the imatinib 179 
only arm, 24/30 patients were in MMR or better, and 6/30 not in MMR; in the IM/HCQ arm, 28/30 180 
patients were in MMR, and 5 were not in MMR. At 12 months, within the high baseline group, the 181 
‘success’ rate in the IM/HCQ arm was 4.7% higher than in the IM alone arm (95% CI: 26.5% lower to 182 
32.2% higher; unadjusted 2-sided p-value > 0.99; FDR adjusted 2-sided p-value > 0.99), and within the 183 
low baseline BCR-ABL group, the ‘success’ rate in the IM+HCQ arm is 10.5% lower than in the IM alone 184 
arm (95% CI: 34.6% lower to 16.4% higher; unadjusted 2-sided p-value = 0.61; FDR adjusted 2-sided p-185 
value > 0.99). At 24 months, this difference is more striking, and the ‘success’ rate in the IM+HCQ arm is 186 
34.6% higher than in the IM alone arm in those with high baseline BCR-ABL (95% CI: 0.5% higher to 187 
58.3% higher; unadjusted 2-sided p-value = 0.066; FDR adjusted 2-sided p-value = 0.26), and 3.8% higher 188 
in the low baseline BCR-ABL subgroup (95% CI: 23.4% lower to 32.3% higher; unadjusted 2-sided p-value 189 
> 0.99; FDR adjusted 2-sided p-value > 0.99) (figure 2).  This suggests that the kinetics of response is 190 
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determined by BCR-ABL1:ABL1 ratio at trial entry and those with higher baseline levels may benefit 191 
more from the addition of HCQ to IM. 192 
Similarly, in a post hoc analysing utilising the median BCR-ABL1:ABL1 ratio at trial entry, we analysed the 193 
proportion of patients achieving a deep molecular response (DMR), as defined by MR3, MR4, MR4.5, 194 
and MR5, at both 12 and 24 months.  There was no significant difference in those achieving DMR 195 
between experimental arms of ‘high’ and ‘low’ BCR-ABL1 expressors.  However, there was a higher 196 
trend for achievement of DMR within the IM/HCQ arm, particularly at 24 months (table SI) where the 197 
proportion of patients in the ‘high’ BCR-ABL1 subgroup achieving MR3 was 26.0% higher in the IM/HCQ 198 
arm (95% CI: 7.7% lower to 53.6% higher; unadjusted 2-sided p-value = 0.26; FDR adjusted 2-sided p-199 
value = 0.85); MR4, 17.9% higher in the combination arm (95% CI: 13.9% lower to 43.4% higher; 200 
unadjusted 2-sided p-value = 0.41; FDR adjusted 2-sided p-value = 0.85); MR4.5, 16.7% higher in the 201 
combination arm (95% CI cannot be computed; unadjusted 2-sided p-value = 0.25; FDR adjusted 2-sided 202 
p-value = 0.85); and MR5,  11.1% higher in the combination arm (95% CI cannot be computed; 203 
unadjusted 2-sided p-value = 0.50; FDR adjusted 2-sided p-value = 0.85).  Interpretation of this needs to 204 
be carefully considered as this will be underpowered by the very nature of a post hoc analysis.   205 
Plasma levels: 206 
To ensure that HCQ did not interfere with IM plasma levels, and that patients were achieving an 207 
adequate dosage of HCQ, plasma levels of drugs in both study arms were determined.  IM plasma levels 208 
were assessed in the ITT population, excluding the 12 patients (n=6 in both arms) in the safety run-in 209 
period where blood samples were not taken, and those that withdrew consent.  Plasma levels were 210 
taken 20 to 26 hours after the last dose of drug in cycles 1, 2, 4, 7, 10, and 13.  There was no significant 211 
difference, with an adjustment for multiple comparisons using the FDR approach, in trough IM levels 212 
between the arms at any time-point.  However, there was a trend towards increased CGP metabolite 213 
(IM metabolite) plasma levels relative to baseline at all time-points in the IM/HCQ arm compared to IM 214 
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alone. These differences reached statistical significance at the 2-sided 10% level at cycle 2 (unadjusted 215 
2-sided p=0.032; FDR adjusted 2-sided p=0.090) and cycle 13 (unadjusted 2-sided p=0.036; FDR adjusted 216 
2-sided p=0.090) (figure S1A).   217 
HCQ plasma levels were aiming to achieve a trough concentration of >2000ng/ml at the time points 218 
described above.  Only 47.1% (n=8/17) achieved this trough HCQ plasma concentration at any time point 219 
during the 12 months of IM/HCQ treatment.  There was no correlation between the likelihood of 220 
achieving treatment ‘success’ and achieving this trough HCQ concentration (figure S1B).   221 
Autophagy inhibition was additionally determined ex vivo using the lipidated form of microtubule-222 
associated protein 1 light chain 3B (LC3B-II) levels as a marker of autophagosomes.  Bone marrow and 223 
PB samples were collected at baseline, 6 and 12 months (table SII).  In line with recent findings 224 
demonstrating increased autophagy flow in primitive CML cells 23, the number of LC3B-II puncta was 225 
significantly increased in BM derived CD34+ samples, when compared with PB mononuclear cells 226 
(p=0.002) (figure S2A).  LC3B-II puncta were often undetectable in PB and, as expected, ex vivo HCQ 227 
treatment was required to determine LC3B-II expression (figure S2B).  We demonstrated no linear 228 
correlation with trough IM/HCQ levels and degree of LC3B-II levels (data not shown). We did not 229 
demonstrate a reduction in colony-forming cell or long-term culture-initiating cell potentiation with 230 
IM/HCQ compared with IM alone (figure S2C, D).   231 
Safety analysis: 232 
Recruitment was temporarily stopped for 6 weeks once 6 patients were randomly allocated to IM/HCQ 233 
to monitor for evidence of DLTs.  No evidence of toxicity at a dose of HCQ 800mg/day was determined.   234 
Toxicity was graded according to the CTCAE v4.0, and the worst grade determined for each patient in 235 
the first 12 months of treatment (figure 3A) and the 12 months follow-up (figure 3B). Treatment was 236 
generally well tolerated.  During treatment, 4/29 treated patients developed hyponatraemia with IM (3 237 
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at  grade 3 [1 present at grade 1 pre-treatment] and 1 grade 1), compared with 0/32 on IM/HCQ 238 
(p=0.031).  Diarrhoea was more common, with higher CTCAE grade, in the IM/HCQ arm with 21/32 239 
patients affected (10 grade 1, 8 grade 2, and 3 grade 3) compared with 7/29 patients on IM alone (6 240 
grade 1 and 1 grade 2; p = 0.00031).  Grade 1 musculoskeletal problems were seen with IM (n=8), but 241 
not with IM/HCQ (p=0.0015).  There were no cases of retinopathy documented within the IM/HCQ 242 
cohort.   243 
During the trial period, 17 serious adverse events (SAEs) were reported; four were considered serious 244 
adverse reactions (SARs).  Within the IM arm, dyspepsia was reported.  Three SARs occurred in the 245 
IM/HCQ arm, and included one case each of cardiac rhythm disorder, dyspnoea, and heart failure.  246 
Cardiac function fully recovered following discontinuation of HCQ in the patient with heart failure. 247 
No dose reductions for IM were recorded for any patients during the study.  Eleven patients (n=4 on IM, 248 
and n=7 on IM/HCQ) discontinued with ‘on trial’ IM treatment.  The reasons included consent 249 
withdrawal (n=6), rising BCR-ABL1 (n=2), sub-optimal IM plasma levels (n=1), patient choice (n=1 on 250 
IM/HCQ), and other medical conditions (depression CTCAE grade 2, n=1). Within the IM/HCQ arm, 6 251 
patients had a total of 8 HCQ dose reductions (4 patients had 1 reduction, 2 patients had 2 reductions).  252 
Dose reductions were related to diarrhoea (n=5), fatigue (n=2), and patient choice (n=1). Twenty-five 253 
patients completed the 12 cycles of HCQ. Seven patients stopped HCQ before the end of the scheduled 254 
12 cycles, due to withdrawing consent (n=4), treatment-related toxicity (depression and insomnia (both 255 
CTCAE grade 2), n=2) and rising BCR-ABL1 (n=1). Overall the IM/HCQ combination was safe and well 256 
tolerated and side effects were manageable. 257 
 258 
 259 
 260 
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 261 
Discussion: 262 
It has been estimated that 30% of patients on TKI therapy fail to achieve a major molecular response at 263 
2 years 24.  Furthermore, the incidence of progression to blast crisis under TKI treatment ranges between 264 
0.7 and 4.5% per annum 25-27.  One mechanism postulated to contribute to this lack of TKI response is 265 
the phenomenon of disease persistence, which suggests that despite a targeted therapeutic approach, 266 
BCR-ABL-independent mechanisms are being exploited to sustain the survival of CML LSCs 5, 28, 29.  267 
Autophagy has emerged as a critical factor in resistance to a number of chemotherapeutic agents and is 268 
an attractive approach in targeting CP-CML LSCs 15, 16.  In CML, reports suggest that BCR-ABL is a negative 269 
regulator of autophagy, with autophagy being induced following in vitro TKI treatment, and in vitro 270 
pharmacological autophagy inhibition enhances the effect of TKI on functionally defined CML stem cells 271 
15, 30.  Other studies have demonstrated that BCR-ABL promotes autophagosome formation and that 272 
autophagy is essential for BCR-ABL-dependent leukemogenesis 31, 32, suggesting that BCR-ABL may affect 273 
autophagy differently during malignant transformation and progression, as has been suggested in other 274 
malignancies 33.  Together, this suggests that combination treatment with TKI and autophagy inhibition 275 
may lead to higher rates of sustained molecular response and reduced rates of molecular and clinical 276 
progression.  277 
 278 
This phase II clinical trial was designed to compare the combination of IM and HCQ, with standard-of-279 
care IM in CP-CML patients in MCyR with residual disease detected by qPCR.  IM was used as, 280 
internationally, it remains the most commonly administered first-line therapy in CP-CML, and at the 281 
time of trial opening in 2010 and during early recruitment, it was the only approved TKI for first-line 282 
therapy in the UK.  To date, and to our knowledge, this has been the largest autophagy trial in any 283 
malignancy and the first in leukaemia.   284 
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 285 
The primary study end-point was defined as patients who had ≥0.5 log reduction in their 12-month BCR-286 
ABL1 qPCR levels from trial entry (‘successes’).  This endpoint is not conventionally used as a criterion 287 
clinically to evaluate efficacy of treatment response in a CML population.  However,  it is well 288 
documented that in CML patients with an IM-induced complete cytogenetic response, a minimum of a 289 
half-log increase in BCR-ABL RNA (including loss of MMR) is a significant risk factor for future loss of 290 
complete cytogenetic response 34.  It was, therefore, felt that a reduction of this magnitude would be 291 
clinically significant.  There was no statistical difference in ‘success’ rates between IM and IM/HCQ arms 292 
at 12 months.  However, there was an increasing trend towards MMR in the IM/HCQ arm, and the 293 
number of ‘successes’ was 20.8% higher with IM/HCQ at 24 months (1-sided p=0.059 2-sided p = 0.090).   294 
A major difficulty in the interpretation of combination treatment efficacy is the significant heterogeneity 295 
of BCR-ABL1:ABL1 transcripts at trial entry in both experimental arms, despite the depth of response 296 
being taken into consideration during the randomisation process.  This is particularly relevant in view of 297 
the kinetic response that exists during TKI therapy, with a steeper slope and ‘faster’ kinetics noted until 298 
MMR is achieved.  At trial entry, 47.2% and 31.3% of patients were not in MMR in IM and IM/HCQ arms, 299 
respectively.  As stated  above, however, combination treatment demonstrated a higher proportion of 300 
treatment ‘successes’, which is therefore likely to represent clinical significance.  To evaluate this 301 
further, in a post hoc analysis, we demonstrated that those patients with ‘high’ expression of BCR-ABL1 302 
(defined as >0.0305%, as based on the median level at trial entry) in the combination treatment arm 303 
were more likely to achieve both treatment ‘success’ and DMR at 12 and 24 months, suggesting that 304 
further research into autophagy inhibition in combination with TKI is warranted in those patients not 305 
achieving optimal treatment milestones on TKI alone. 306 
15 
 
Our results demonstrate that there may be a clinical advantage for 48 weeks IM/HCQ treatment on 307 
prolonged follow-up, with greatest effect noted at 24 months.  This is intriguing as patients at 24 months 308 
were no longer taking combination treatment, suggesting that the effect of autophagy inhibition was 309 
long-lasting.  We could hypothesise that this is due to alterations in the quiescent phenotype of the CML 310 
LSC leading to greater TKI response with prolonged use.  This is similar to other trials targeting CML-LSCs 311 
where deeper and significant BCR-ABL1 transcript response was seen on prolonged follow-up (5 years) 312 
35.  However, we did not establish autophagy inhibition in in vitro assays at 12 or 24 months, and in 313 
future work in this field, perhaps extending ex vivo assays to later timepoints, as well as including 314 
alternative cellular mechanisms, such as senescence, could be considered to more clearly define the 315 
changes in the functional properties of CML stem cells as a result of prolonged treatment of patients 316 
with autophagy inhibitors and continuing subsequent therapies.   317 
As this was a randomised phase II trial, albeit with relatively small sample size, small treatment 318 
improvements will not be detected, and therefore the increasing trend towards MMR could be clinically 319 
significant.  Furthermore, as described above, differences in TKI kinetic response needs to be considered 320 
in future clinical trials in this field, as well as the challenges in recruitment and trial dropouts (or 321 
‘failures’) which meant the power to drive a robust statistical response was not achieved.  There are 322 
increasing barriers in recruitment to CP-CML studies.  Firstly, this is generally a ‘well’ population, who 323 
tolerates TKI treatment, has few follow-up appointments, and is challenged with a low rate of 324 
progression.  Clinical trials in CP-CML confer increased hospital attendance, with more procedures, 325 
including bone marrow aspirates that are psychologically unappealing.  However, as demonstrated by 326 
the frequent molecular recurrence seen in patients attempting TFR 11, 12, 36, 37, there is an unmet clinical 327 
need to develop therapies capable of targeting the CML LSC which is believed to be the cause of 328 
molecular recurrence, and enable more patients to obtain DMR and successfully maintain TFR.   329 
 330 
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Importantly, the combination of IM/HCQ was well tolerated and no DLTs were observed, although 331 
increased numbers of patients developed grade 1-3 diarrhoea, consistent with previous clinical trials 332 
using HCQ 38-41.  Diarrhoea and fatigue were the main reasons for dose reduction of HCQ, both 333 
recognised adverse effects 39, 42.  Interestingly, compared with IM alone, no patients developed 334 
musculoskeletal AEs with IM/HCQ compared with 8/29 on IM,  in keeping with its known clinical utility in 335 
rheumatological disorders 43.  To our surprise, 4/29 patients developed hyponatraemia with IM alone.  336 
Although not identified as a significant toxicity in the IRIS clinical trial (NCT00006343) 44, hyponatraemia 337 
is recognised as an uncommon adverse event (>1:1000 to < 1:100) of imatinib therapy 45. 338 
 339 
Measuring autophagy flux accurately in PB is difficult, and functional assessment is therefore 340 
problematic.  Plasma levels of HCQ were taken to determine therapeutic dosing, with target trough 341 
levels >2000ng/ml.  However, very recently published in vitro data from our group indicates that even if 342 
this was accomplished, at this trough concentration (equivalent to 5.9µM) complete autophagy 343 
inhibition may not be achieved 23.  This data was not available when the trial was conducted. 344 
Furthermore, consistent HCQ plasma concentrations were not achieved within our trial population and 345 
large interpatient variability in HCQ levels has been demonstrated in a recent clinical trial, in 346 
combination with everolimus, in renal cell cancer 38.  Together, this perhaps explains the lack of 347 
correlation with in vitro assessment; an issue that has been previously demonstrated within solid 348 
tumours 46-48.   A major drawback to HCQ dose optimisation and ultimate achievement of autophagy 349 
inhibition is the risk of adverse effects when using higher doses for longer durations, particularly 350 
retinopathy 39, 49.  Retinopathy is unlikely to occur with dosages less than 6.5mg/kg/day within the first 351 
10 years of therapy 40; we demonstrated no cases of retinopathy. 352 
 353 
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To overcome both inconsistent autophagy inhibition and mitigation of side effects, more potent and 354 
specific autophagy inhibitors are required.  These are beginning to be assessed in pre-clinical models 23, 355 
50, 51. CQ derivatives, such as Lys05, have been shown to be 3- to 10-fold more potent and have good 356 
effect in CML models. Within murine models, however, higher doses, led to Paneth cell dysfunction and 357 
intestinal obstruction 23, 51.  As yet, these have not been translated to clinical trial.  358 
 359 
We conclude that while HCQ (at 400-800mg daily) in combination with IM is a safe and tolerable 360 
treatment option in CP-CML, the primary endpoint of this study was not met, in part due to difficulties in 361 
recruitment and retention within the trial and in part due to failure to achieve adequate HCQ plasma 362 
levels.  Our study suggests that clinically achievable doses of HCQ are unlikely to achieve a sufficient 363 
trough plasma concentration to accomplish meaningful autophagy inhibition. However, with more 364 
potent and specific autophagy inhibitors on the horizon and in preclinical development, this may be 365 
worth pursuing in future clinical trials with the aim to eradicate the CP-CML LSC. 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
 377 
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 379 
 380 
Figure Legends 381 
Figure 1. Trial CONSORT diagram. IM = Imatinib; IM/HCQ = Imatinib and Hydroxychloroquine; Rx = 382 
treatment 383 
Figure 2. Plot of median BCR-ABL1:ABL1 ratio (with upper and lower quartiles denoted by vertical 384 
bars) over the study period, split by treatment arm. Separate trend lines are shown for each treatment 385 
arm, for patients with baseline BCR-ABL greater than (“high” group) and less than or equal to (“low” 386 
group) the overall median value.  Individual patient data (jittered) are overlaid. Values that are recorded 387 
as undetectable (zero) have been censored at 0.001% – the censored ranges are denoted by dotted lines 388 
Figure 3. (A) Butterfly plot illustrating prevalence of selected haematology and biochemistry toxicities 389 
and adverse events during the first 12 months of treatment. Toxicities and adverse events present at 390 
any grade and at worse grade (≥ 2) are presented and restricted to toxicities and adverse events where 391 
at least 10% of patients on either arm experience worse grade during the first 12 months of treatment. 392 
(B) Butterfly plot illustrating prevalence of selected haematology and biochemistry toxicities and 393 
adverse events during the 12 months follow-up period. Toxicities and adverse events present at any 394 
grade and at worse grade (≥ 2) are presented and restricted to toxicities and adverse events where at 395 
least 10% of patients on either arm experience worse grade during the 12 months follow-up period.  The 396 
2-sided p-value from a Mann-Whitney test comparing the distribution of grades between treatment 397 
arms is presented for each CTCAE-defined toxicity.  Significant change between arms are depicted (*). 398 
 399 
Table I. Exclusion criteria 400 
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Table II. Baseline demographics and disease characteristics. Data are presented as median or n (%). IM 401 
= Imatinib; HCQ = Hydroxychloroquine; ECOG = Eastern Cooperative Oncology Group.  402 
Table III. Molecular response rates at 12 and 24 months in IM versus IM/HCQ arms. ‘Success’ rates 403 
were determined by ≥0.5 log reduction in BCR-ABL1:ABL1 ratio between arms. Patients who withdrew 404 
before assessment or who had an increase in dose prior to assessment were classified as ‘failures’.  405 
Complete molecular response (CMR) was defined as undetectable BCR-ABL1 in the presence of at least 406 
10,000 ABL1 control transcripts.  Major molecular response (MMR) was defined a BCR-ABL1:ABL1 ratio 407 
consistently ≤0·1%. IM = Imatinib; IM/HCQ = Imatinib and hydroxychloroquine. 408 
 409 
Supplemental figure legends (online only) 410 
Figure S1. Ratio of CGP metabolite to IM, and HCQ plasma levels. (A) Ratio of current to baseline CGP 411 
to IM levels over sequential cycle follow-up. No correlation was detected between ratio and treatment 412 
cohort. (B) HCQ concentration (ng/ml) did not correlate with ‘success’ or ‘failure’ rates. IM = Imatinib; 413 
HCQ = Hydroxychloroquine. 414 
Figure S2. In vitro autophagy and functional response on HSPC population. (A) Percentage of LC3B-II 415 
puncta positive cells by IF in CD34+ BM cells versus unselected PB (p=0.002). (B) Western blotting of 416 
LC3B-II and GAPDH in 3 patient samples (pt 42.6 – BM; pt 47 – BM; pt 60 – PB and BM) untreated and 417 
treated in vitro with HCQ. (C) Change from baseline in percentage of colonies by CFC analysis from 418 
CD34+-selected BM populations at 6 and 12 months in IM and IM/HCQ cohort. (D) Change from baseline 419 
in the percentage of colonies by LTC-IC analysis from CD34+-selected BM populations at 6 and 12 420 
months in IM and IM/HCQ cohort. HSPC = haemopoietic stem and progenitor cell; IM = Imatinib; HCQ = 421 
Hydroxychloroquine. 422 
Table SI. Proportion of DMR split by ‘high’ and ‘low’ baseline BCR-ABL1:ABL1 ratio according to 423 
median ratio at trial entry 424 
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Table SII. Sample number used in in vitro experiments 425 
 426 
 427 
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Figure 1. CONSORT diagram
62 patients 
enrolled
30 in IM cohort 32 in IM/HCQ cohort
Did not start 
protocol Rx
(n=1)*
Did start 
protocol Rx
(n=29)
Did start 
protocol Rx
(n=32)
4 dropped out
1 withdrew consent
3 physician decision**
25 completed 12 months Rx
7 dropped out
5 withdrew consent
2 physician decision***
5 lost to follow-up 
20 continuing IM 
beyond 24 months
19 continuing IM 
beyond 24 months
6 lost to follow-up
*withdrew consent prior to initiation of study; received no treatment on study
** 1 due to rising BCR-ABL PCR, 1 due to low IM plasma levels leading to increased dose, and 1 change 
to second generation TKI
*** 1 due to rising BCR-ABL PCR, and 1 due to another co-morbidity (depression)
25 completed 12 months Rx
Figure 2. Plot of median BCR-ABL % (with upper and lower quartiles denoted by vertical bars) over the study period, split by treatment arm. 
 
 
Figure 3A. Butterfly plot illustrating prevalence of selected haematology and biochemistry toxicities and adverse events during the first 12 months of 
treatment. 
 
* denotes a statistically significant difference in the distribution of worst grades over the period between the arms at the 2-sided 5% significance level, 
assessed by the Mann-Whitney U test.  
 
 
  
Figure 3B. Butterfly plot illustrating prevalence of selected haematology and biochemistry toxicities and adverse events during the 12 months follow-up 
period. 
 
Table I. Exclusion criteria 
 
Exclusion criteria 
Patient who have been treated with Imatinib <12 months or patients who have 
changed dose in previous 6 months 
Impaired cardiac function including any one of the following: 
• Screening ECG with a QTc >450 msec 
• Patients with congenital long QT syndrome 
• History or presence of sustained ventricular tachycardia 
• Any history of ventricular fibrillation or torsades de pointes 
• Congestive heart failure (NY Heart Association class III or IV) 
• Uncontrolled hypertension 
Patients with severe GI disorder, uncontrolled epilepsy, known G6PD deficiency, 
known porphyria, moderate or severe psoriasis, known myasthenia gravis or other 
concurrent severe and/or uncontrolled medical conditions 
Patients who have received chemotherapy, any investigational drug or undergone 
major surgery <4 weeks prior to starting study drug or who have not recovered from 
side effects of such therapy 
Concomitant use of any other anti-cancer therapy or radiation therapy 
Patients who have a pre-existing maculopathy of the eye 
Female patients who are pregnant or breast feeding or patients of reproductive 
potential not willing to use a double method of contraception including a barrier 
method (i.e. condom) during the study and 3 months after the end of treatment. 
(Patients should continue with standard contraceptive precautions beyond the study 
period as per Imatinib) 
Women of childbearing potential (WOCBP) must have a negative serum pregnancy 
test within 7 days of the first administration of oral HCQ 
Male patients whose sexual partners are WOCBP not willing to use a double method of 
contraception including condom during the study and 3 months after the end of 
treatment on study. (Patients should continue with standard contraceptive 
precautions beyond the study period as per Imatinib) 
Patients with any significant history of non-compliance to medical regimens or with  
inability to grant a reliable informed consent 
 
Table II. Baseline Demographics and Disease Characteristics 
Baseline characteristic IM (n = 30) IM/HCQ (n = 32) 
Median age, years (IQR) 49.5 (42.0 – 66.0)  50.0 (38.5 – 60.5) 
Gender 
     Female 
     Male 
 
33.3% 
66.7% 
 
28.1% 
71.9% 
Ethnicity 
     White 
     Afro /Caribbean 
 
93.1% 
6.9% 
 
100.0% 
0.0% 
ECOG 
     0  
     1 
 
93.1% 
6.9% 
 
87.5% 
12.5% 
IM dose at trial entry 
     400mg 
     600mg 
     800mg 
 
90.0% 
6.7% 
3.3% 
 
84.4% 
12.5% 
3.1% 
Median time on IM pre-trial  
Entry, months (IQR) 
52.2 (32.8 – 110.0) 49.7 (27.5 – 89.0) 
Response to imatinib at trial entry 
     Complete haematological response 
     Partial cytogenetic response 
     Major cytogenetic response 
     Complete cytogenetic response 
     Major molecular response 
     Deep molecular response 
     Unknown 
 
10.0% 
3.3% 
3.3% 
30.0% 
50.0% 
0.0% 
3.3% 
 
0.0% 
0.0% 
6.3% 
25.0% 
62.5% 
0.0% 
6.3% 
Additional chromosomal abnormalities 6.7%* 9.4%** 
 
NOTE. Data presented as percentage, or median (with IQR).  
IM is Imatinib; HCQ is hydroxychroroquine; IQR is inter-quartile range (the 25th and 75th percentiles). * one patient on imatinib only had a 
variant Philadelphia chromosome translocation, and one had a deletion of chromosome 12.   **one patient on IM/HCQ had trisomy 21, one 
had a double Phliadelphia chromosome abnormality and one had a deletion of chromosome 9. 
 
Table III. Molecular response rates at 12 and 24 months in the IM versus IM/HCQ arms. 
 
 Study arm 
IM IM/HCQ 
No. of patients % No. of patients % 
12 month 'success'/'failure' 
status (1-sided p=0.58; 2-
sided p=0.99) 
Success 6 20.0% 6 18.8% 
Failure 24 80.0% 26 81.3% 
Reason for treatment 
‘failure’ at 12 months 
Failed to 
achieve >0.5 
log reduction 
19 79.2% 19 73.1% 
Increase in IM 
dose 
1 4.2% 0 0.0% 
Withdrew  4 16.7% 7 26.9% 
24 month ‘success’/’failure’ 
status (1-sided p=0.059; 2-
sided p=0.090) 
Success 5 16.7% 12 37.5% 
Failure 25 83.3% 20 62.5% 
Reason for treatment 
‘failure’ at 24 months 
Failed to 
achieve >0.5 
log reduction 
19 76.0% 13 65.0% 
No data 1 4.0% 0 0.0% 
Increase in IM 
dose 
1 4.0% 0 0.0% 
Withdrew 4 16.0% 7 35.0% 
Molecular response at 12 
months (1-sided p=0.43; 2-
sided p=0.78) 
CMR 0 0.0% 0 0% 
MMR 20 66.7% 23 71.9% 
No molecular 
response 
5 16.7% 2 6.3% 
Missing data 5 16.7% 7 21.9% 
Molecular response at 24 
months (1-sided p=0.33; 2-
sided p=0.58) 
CMR 1 3.3% 2 6.3% 
MMR 19 63.3% 22 68.8% 
No molecular 
response 
4 13.3% 1 3.1% 
Missing data 6 20.0% 7 21.9% 
 
